IV ceftriaxone

Phase 3Small molecule

RRESnTEC, Institute of Research

IV ceftriaxone is one of 97 small molecule programs targeting Malaria. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MalariaActive, not recruiting

PneumoniaActive, not recruiting

Urinary Tract InfectionActive, not recruiting

MalariaPreclinical

Active, not recruiting

PneumoniaPhase 3

Active, not recruiting

Urinary Tract InfectionPhase 3

Active, not recruiting

Competition

Competitive Landscape

547 competitors in Pneumonia

#DrugCompanyPhaseTrials

IV ceftriaxone

RRESnTEC, Institute of Research

Phase 3

1 2

Primaxin

Pfizer

Preclinical

2 3

Jakafi

Incyte

Preclinical

1 4

Primaquine

Sanofi

Preclinical

1 5

Acanya

Pfizer

Preclinical

1 6

Prevacid

Takeda

Preclinical

1 7

Innohep

Alnylam Pharmaceuticals

Preclinical

1 8

Avlosulfon

AAlmirall, S.A.

Preclinical

4 9

Neutrexin

WWest Japan Thoracic Oncology Group

Preclinical

12 10

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Malaria1 trial

Efficacy of Only IV Artesunate Versus IV Artesunate Plus IV Quinine in the Treatment of Severe Malaria in Children: A Comparative Study

Completed·RRESnTEC, Institute of Research·N/A·NCT06472258·104 enrolled

TED1 trial

Pharmacokinetic and Safety Study of HYLENEX Recombinant-Augmented Subcutaneous Ceftriaxone Administration

Completed·BBaxter Healthcare Corporation·Phase 1·NCT00493220·30 enrolled

Pneumonia1 trial

Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia

Completed·FForest Laboratories·Phase 3·NCT00621504·606 enrolled

Intravenous1 trial

Comparison of Efficacy of Oral Amoxicillin Versus Intravenous Ceftriaxone

Not yet recruiting·RRESnTEC, Institute of Research·N/A·NCT06532409·114 enrolled

Urinary Tract Infection1 trial

Oral vs Initial Intravenous Antibiotic Treatment of Urinary Tract Infections in Children: a RCT

Terminated·UUniversity of Padova·Phase 3·NCT00161330·440 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for IV ceftriaxone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IV ceftriaxone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IV ceftriaxone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — RESnTEC, Institute of Research company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: RRESnTEC, Institute of Research

IV ceftriaxone

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Malaria1 trial

TED1 trial

Pneumonia1 trial

Intravenous1 trial

Urinary Tract Infection1 trial

References

Drug Info

Quick Facts

Related News